MA51046A - Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc - Google Patents
Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du sncInfo
- Publication number
- MA51046A MA51046A MA051046A MA51046A MA51046A MA 51046 A MA51046 A MA 51046A MA 051046 A MA051046 A MA 051046A MA 51046 A MA51046 A MA 51046A MA 51046 A MA51046 A MA 51046A
- Authority
- MA
- Morocco
- Prior art keywords
- pregan
- deuterates
- pyrazol
- cyano
- alpha
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762596725P | 2017-12-08 | 2017-12-08 | |
| US201862731539P | 2018-09-14 | 2018-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51046A true MA51046A (fr) | 2021-03-17 |
Family
ID=65003476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051046A MA51046A (fr) | 2017-12-08 | 2018-12-07 | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20200291059A1 (fr) |
| EP (2) | EP4484440A3 (fr) |
| JP (4) | JP2021505608A (fr) |
| KR (1) | KR20200096596A (fr) |
| MA (1) | MA51046A (fr) |
| WO (1) | WO2019113494A1 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| RS62761B1 (sr) | 2012-08-21 | 2022-01-31 | Sage Therapeutics Inc | Alopregnanolon za lečenje refraktornog epileptičkog statusa |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (fr) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions et procédés pour traiter des troubles du snc |
| WO2018013613A1 (fr) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| TW202604538A (zh) | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| US12325726B2 (en) | 2018-12-17 | 2025-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2021023213A1 (fr) * | 2019-08-07 | 2021-02-11 | 上海翰森生物医药科技有限公司 | Sel et forme cristalline d'un régulateur de dérivé de stéroïde |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| CN115551514A (zh) | 2020-03-25 | 2022-12-30 | 萨奇治疗股份有限公司 | 用于治疗呼吸系统病症的药物的用途 |
| US20230416300A1 (en) * | 2020-08-20 | 2023-12-28 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP2025508406A (ja) | 2022-02-16 | 2025-03-26 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ関連障害を処置するための神経活性ステロイド |
| US20250177418A1 (en) | 2022-02-28 | 2025-06-05 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR100477070B1 (ko) * | 1994-03-25 | 2006-04-21 | 이소테크니카 인코포레이티드 | 중수소화작용에의한의약품의효능강화법 |
| US20100120733A1 (en) * | 2008-11-07 | 2010-05-13 | Auspex Pharmaceuticals, Inc. | Steroid modulators of glucocorticoid receptor |
| EP4717314A2 (fr) | 2011-10-14 | 2026-04-01 | Sage Therapeutics, LLC | 3,3 composés de 19-nor-pregnane disubstitués, compositions et utilisations associées |
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| US20150175651A1 (en) | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| ES2822375T3 (es) * | 2012-06-19 | 2021-04-30 | Intercept Pharmaceuticals Inc | Preparación de la forma no cristalina del ácido obeticólico |
| WO2014028398A2 (fr) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation de crises épileptiques par une polythérapie à l'aide de benzodiazépines et de neurostéroïdes |
| RS62761B1 (sr) | 2012-08-21 | 2022-01-31 | Sage Therapeutics Inc | Alopregnanolon za lečenje refraktornog epileptičkog statusa |
| US20150313915A1 (en) | 2012-11-30 | 2015-11-05 | The Regents Of The University Of California | Anticonvulsant activity of steroids |
| DK2935307T3 (en) | 2012-12-18 | 2018-07-30 | Univ Washington | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS USED IN METHODS OF TREATMENT |
| GB201302368D0 (en) * | 2013-02-11 | 2013-03-27 | Univ Bath | Compound |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| WO2014169836A1 (fr) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor-stéroïdes neuroactifs et procédés d'utilisation de ceux-ci |
| CN117304245A (zh) | 2013-04-17 | 2023-12-29 | 萨奇治疗股份有限公司 | 刺激神经活性的19-去甲类固醇及其使用方法 |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| CA2918735C (fr) | 2013-07-19 | 2023-08-01 | Sage Therapeutics, Inc. | Steroides neuroactifs, compositions, et leurs utilisations |
| CN105579043B (zh) | 2013-08-23 | 2021-09-14 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物和其用途 |
| SI3705488T1 (sl) | 2014-05-29 | 2022-10-28 | Sage Therapeutics, Inc. | Nevroaktivni steroidi, sestavki in uporaba le-teh |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| MY190408A (en) | 2014-10-16 | 2022-04-21 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| US20170233433A1 (en) * | 2014-10-16 | 2017-08-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2016082789A1 (fr) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions et procédés pour traiter des troubles du snc |
| LT3250210T (lt) | 2015-01-26 | 2021-04-12 | Sage Therapeutics, Inc. | Kompozicijos ir būdai, skirti gydyti cns sutrikimus |
| CN105985396A (zh) * | 2015-02-16 | 2016-10-05 | 苏州泽璟生物制药有限公司 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
| DK3258939T3 (da) | 2015-02-20 | 2022-12-12 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser heraf |
| EP3280420B1 (fr) | 2015-04-10 | 2024-03-27 | Sage Therapeutics, Inc. | Compositions et méthodes permettant de traiter des troubles du snc |
| AR105044A1 (es) | 2015-06-18 | 2017-08-30 | Sage Therapeutics Inc | Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente |
| MA43284A (fr) | 2015-11-20 | 2018-09-26 | Sage Therapeutics Inc | Composés et leurs méthodes d'utilisation |
| PH12018501923B1 (en) | 2016-03-08 | 2024-06-28 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| WO2018013613A1 (fr) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| CA3030420C (fr) | 2016-07-11 | 2025-11-18 | Sage Therapeutics, Inc. | Steroides neuroactifs substitues en c7, c12 et c16 et methodes d'utilisation associees |
| TW202604538A (zh) | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3678670A1 (fr) | 2017-09-07 | 2020-07-15 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs et leurs méthodes d'utilisation |
| WO2019051477A1 (fr) | 2017-09-11 | 2019-03-14 | Sage Therapeutics, Inc. | Méthodes de traitement de l'épilepsie ou de l'état de mal épileptique |
| US20220110949A1 (en) | 2017-09-14 | 2022-04-14 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3728285B1 (fr) | 2017-12-22 | 2026-04-08 | Sage Therapeutics, LLC | Compositions et méthodes permettant de traiter les troubles du snc |
| CA3086299A1 (fr) | 2017-12-22 | 2019-06-27 | Sage Therapeutics, Inc. | Compositions et methodes permettant de traiter des troubles du snc |
| JP7538040B2 (ja) | 2018-01-12 | 2024-08-21 | セージ セラピューティクス， インコーポレイテッド | ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物 |
| WO2019241442A1 (fr) | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | 19-nor stéroïde c21-n-pyrazolyle disubstitué en c3,3 et procédés d'utilisation de celui-ci |
| AU2019357040B2 (en) | 2018-10-12 | 2025-03-27 | Sage Therapeutics, Inc. | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders |
| EP4606812A3 (fr) | 2018-10-19 | 2025-10-15 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs 9(11)-insaturés et leurs procédés d'utilisation |
| IL312610B2 (en) | 2018-12-05 | 2026-05-01 | Sage Therapeutics Llc | Neuroactive steroids and methods of using them |
| TWI848034B (zh) | 2018-12-21 | 2024-07-11 | 美商賽吉醫療公司 | 神經活性類固醇及其組合物 |
| TWI855081B (zh) | 2019-05-24 | 2024-09-11 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| JP7670626B2 (ja) | 2019-05-31 | 2025-04-30 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド及びその組成物 |
| CA3143545A1 (fr) | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Composes pour le traitement de troubles du systeme nerveux central |
| JP7787635B2 (ja) | 2019-06-27 | 2025-12-17 | セージ セラピューティクス， エルエルシー | Ｃｎｓ障害を治療するための組成物及び方法 |
| BR112021026447A2 (pt) | 2019-06-27 | 2022-04-12 | Sage Therapeutics Inc | Composições e métodos para tratamento de distúrbios de cns |
| US20230018765A1 (en) | 2019-12-05 | 2023-01-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| WO2021168106A1 (fr) | 2020-02-18 | 2021-08-26 | Praxis Precision Medicines, Inc. | Neurostéroïde deutéré |
| AU2021238346A1 (en) | 2020-03-18 | 2022-09-29 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| CN115551514A (zh) | 2020-03-25 | 2022-12-30 | 萨奇治疗股份有限公司 | 用于治疗呼吸系统病症的药物的用途 |
| CN115768781A (zh) | 2020-06-24 | 2023-03-07 | 萨奇治疗股份有限公司 | 3.α.-羟基,17.β.-C(O)-N-芳基取代的神经活性类固醇及其组合物 |
| CA3187178A1 (fr) | 2020-07-20 | 2022-01-27 | Sage Therapeutics, Inc. | Formulations de steroide c21-n-pyrazolyle 19-nor c3,3-disubstitue et leurs procedes d'utilisation |
| US20230416300A1 (en) | 2020-08-20 | 2023-12-28 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP4251634A1 (fr) | 2020-11-25 | 2023-10-04 | Sage Therapeutics, Inc. | Compositions et méthodes de traitement de troubles du système nerveux central et application associée |
| WO2022165017A1 (fr) | 2021-01-28 | 2022-08-04 | Sage Therapeutics, Inc. | Utilisation de stéroïdes neuroactifs pour le traitement d'une dysfonction sexuelle |
| WO2022177718A1 (fr) | 2021-02-18 | 2022-08-25 | Sage Therapeutics, Inc. | Utilisation d'un stéroïde neuroactif pour le traitement d'un dysfonctionnement sexuel |
| JP2024510436A (ja) | 2021-03-17 | 2024-03-07 | セージ セラピューティクス， インコーポレイテッド | 大うつ病性障害の処置のための１９－ノルｃ３，３－２置換ｃ２１－ｎ－ピラゾリルステロイド |
| CN117897160A (zh) | 2021-04-12 | 2024-04-16 | 萨奇治疗股份有限公司 | 特发性震颤的治疗 |
| MX2023012727A (es) | 2021-04-29 | 2023-11-08 | Sage Therapeutics Inc | Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto. |
| MX2023012728A (es) | 2021-04-29 | 2023-11-08 | Sage Therapeutics Inc | Esteroide neuroactivo para el tratamiento del trastorno depresivo mayor y la depresion posparto en una mujer lactante. |
| JP2025508406A (ja) | 2022-02-16 | 2025-03-26 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ関連障害を処置するための神経活性ステロイド |
| US20250177418A1 (en) | 2022-02-28 | 2025-06-05 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
-
2018
- 2018-12-07 US US16/770,398 patent/US20200291059A1/en not_active Abandoned
- 2018-12-07 JP JP2020531058A patent/JP2021505608A/ja not_active Withdrawn
- 2018-12-07 MA MA051046A patent/MA51046A/fr unknown
- 2018-12-07 EP EP24200003.2A patent/EP4484440A3/fr active Pending
- 2018-12-07 WO PCT/US2018/064546 patent/WO2019113494A1/fr not_active Ceased
- 2018-12-07 EP EP18830574.2A patent/EP3720867A1/fr not_active Ceased
- 2018-12-07 KR KR1020207019345A patent/KR20200096596A/ko not_active Ceased
-
2021
- 2021-12-08 US US17/545,290 patent/US11667668B2/en active Active
-
2023
- 2023-04-24 US US18/305,529 patent/US12060386B2/en active Active
- 2023-06-06 JP JP2023093131A patent/JP7569412B2/ja active Active
-
2024
- 2024-02-05 JP JP2024015700A patent/JP7837352B2/ja active Active
- 2024-06-27 US US18/756,278 patent/US12534495B2/en active Active
-
2025
- 2025-12-25 JP JP2025282062A patent/JP2026040695A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2026040695A (ja) | 2026-03-09 |
| JP2021505608A (ja) | 2021-02-18 |
| US12534495B2 (en) | 2026-01-27 |
| KR20200096596A (ko) | 2020-08-12 |
| EP4484440A3 (fr) | 2025-03-26 |
| US20250171491A1 (en) | 2025-05-29 |
| US20240092824A1 (en) | 2024-03-21 |
| EP4484440A2 (fr) | 2025-01-01 |
| US12060386B2 (en) | 2024-08-13 |
| JP7569412B2 (ja) | 2024-10-17 |
| JP7837352B2 (ja) | 2026-03-30 |
| US20200291059A1 (en) | 2020-09-17 |
| EP3720867A1 (fr) | 2020-10-14 |
| JP2024033000A (ja) | 2024-03-12 |
| WO2019113494A1 (fr) | 2019-06-13 |
| US11667668B2 (en) | 2023-06-06 |
| JP2023105082A (ja) | 2023-07-28 |
| US20220098231A1 (en) | 2022-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3465212A4 (fr) | Régulation du microbiote intestinal pour le traitement de troubles neurodégénératifs | |
| EP3634417A4 (fr) | Dérivés quinazoline-pyrazole pour le traitement de troubles liés au cancer | |
| EP3423047A4 (fr) | Compositions d'agonistes sélectifs du récepteur cb2 pour le traitement des troubles mentaux | |
| EP3864601A4 (fr) | Techniques pour des transactions de proximité de jeton | |
| EP3570844A4 (fr) | Azolopyrimidine pour le traitement de troubles liés au cancer | |
| EP3893940A4 (fr) | Polythérapie pour le traitement de la dystrophie musculaire | |
| DK3728284T3 (da) | 19-homo, 3.alpha.-hydroxy-steroid-20-on forbindelser til behandling af cns-lidelser | |
| MA50578A (fr) | Systèmes crispr/cas pour le traitement de dmd | |
| EP3481387A4 (fr) | Methodes et compositions pour le traitement de troubles épileptiques | |
| EP3340982A4 (fr) | Composés pour le traitement de troubles immunitaires et inflammatoires | |
| EP3500267A4 (fr) | Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs | |
| MA54925A (fr) | Compositions pour le traitement de troubles acido-basiques | |
| MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
| EP3445451A4 (fr) | Compositions et méthodes pour le traitement de troubles lysosomaux et de troubles caractérisés par un dysfonctionnement lysosomal | |
| MA51139A (fr) | Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer | |
| EP3704108A4 (fr) | Composés et compositions pour le traitement de troubles hématologiques | |
| EP3445352A4 (fr) | Compositions pour le traitement de troubles liés à l'hyperkératose | |
| EP3352749A4 (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| EP3606520A4 (fr) | Inhibiteurs de l'activité de la déshydrogénase à chaîne courte pour le traitement des troubles coronaires | |
| EP3454896A4 (fr) | Dérivés hétérocycliques pour le traitement de rsv | |
| MA51672A (fr) | Composés destinés au traitement des troubles kinases-dépendants | |
| EP3621434A4 (fr) | Méthodes de traitement de troubles neuropsychiatriques | |
| MA52941A (fr) | Dérivés de thiophène pour le traitement de troubles provoqués par ige | |
| MA49140A (fr) | Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques | |
| MA47207A (fr) | Composés utiles pour le traitement de troubles du tractus digestif |